See more : NEUCA S.A. (NEU.WA) Income Statement Analysis – Financial Results
Complete financial analysis of Evolent Health, Inc. (EVH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Evolent Health, Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
- CNFinance Holdings Limited (CNF) Income Statement Analysis – Financial Results
- Genus Power Infrastructures Limited (GENUSPOWER.BO) Income Statement Analysis – Financial Results
- MediaG3, Inc. (MDGC) Income Statement Analysis – Financial Results
- Gujarat State Fertilizers & Chemicals Limited (GSFC.NS) Income Statement Analysis – Financial Results
- Jiangsu Hagong Intelligent Robot Co., Ltd (000584.SZ) Income Statement Analysis – Financial Results
Evolent Health, Inc. (EVH)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.evolenthealth.com
About Evolent Health, Inc.
Evolent Health, Inc., a healthcare company, through its subsidiary, Evolent Health LLC, provides clinical and administrative solutions to payers and providers in the United States. It operates in two segments, Evolent Health Services and Clinical Solutions. The Evolent Health Services segment provides an integrated administrative and clinical platform for health plan administration and population health management. It offers financial and administrative management services, such as health plan services, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients, population health performance that delivers patient-centric cost-effective care. The Clinical Solutions segment offers specialty care management services support a range of specialty care delivery stakeholders during their transition from fee-for-service to value-based care, independent of their stage of maturation and specific market dynamics in oncology and cardiology; and holistic total cost of care improvement. The company was founded in 2011 and is headquartered in Arlington, Virginia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.96B | 1.35B | 907.96M | 1.02B | 846.38M | 627.06M | 434.95M | 254.19M | 96.88M | 0.00 | 25.67M | 8.35M |
| Cost of Revenue | 1.50B | 1.04B | 657.55M | 701.37M | 513.06M | 327.83M | 269.35M | 155.18M | 57.40M | 0.00 | 30.02M | 11.27M |
| Gross Profit | 460.47M | 316.58M | 250.41M | 321.06M | 333.32M | 299.24M | 165.60M | 99.01M | 39.48M | 0.00 | -4.35M | -2.93M |
| Gross Profit Ratio | 23.45% | 23.42% | 27.58% | 31.40% | 39.38% | 47.72% | 38.07% | 38.95% | 40.75% | 0.00% | -16.93% | -35.08% |
| Research & Development | 0.00 | 27.00M | 15.50M | 15.10M | 19.80M | 18.20M | 17.20M | 11.10M | 5.80M | 0.00 | 2.00M | 0.00 |
| General & Administrative | 0.00 | 0.00 | 219.50M | 310.55M | 392.82M | 306.31M | 205.67M | 160.69M | 75.29M | 0.00 | 15.60M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 358.11M | 269.27M | 219.50M | 310.55M | 392.82M | 306.31M | 205.67M | 160.69M | 75.29M | 0.00 | 15.60M | 15.98M |
| Other Expenses | 173.57M | 67.20M | 60.04M | 61.48M | 60.91M | 109.00K | 171.00K | 4.00K | 7.17M | -25.25M | 1.00K | 0.00 |
| Operating Expenses | 531.68M | 336.46M | 279.54M | 372.03M | 453.73M | 350.82M | 238.04M | 177.92M | 82.45M | -25.25M | 16.81M | 16.69M |
| Cost & Expenses | 2.04B | 1.37B | 937.09M | 1.07B | 966.79M | 678.65M | 507.39M | 333.09M | 139.85M | -25.25M | 46.83M | 27.96M |
| Interest Income | 5.26M | 1.37M | 407.00K | 3.16M | 3.99M | 3.44M | 1.66M | 0.00 | 0.00 | 0.00 | 0.00 | 18.00K |
| Interest Expense | 54.21M | 15.57M | 25.43M | 28.34M | 14.53M | 5.48M | 3.64M | 723.00K | 293.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 123.42M | 90.25M | 60.04M | 60.84M | 66.64M | 44.52M | 32.37M | 17.22M | 7.17M | 0.00 | 1.21M | 114.00K |
| EBITDA | -24.79M | 43.75M | 55.66M | -241.38M | -245.95M | -4.15M | -40.40M | -220.31M | -31.51M | -25.25M | -20.35M | -19.51M |
| EBITDA Ratio | -1.26% | 0.54% | 9.94% | 2.31% | -7.73% | -1.32% | -9.20% | 38.10% | -464.44% | 0.00% | -257.85% | -233.70% |
| Operating Income | -71.21M | -59.84M | 30.25M | -37.88M | -120.41M | -47.48M | -72.84M | -237.42M | -42.97M | -25.25M | -21.16M | -19.62M |
| Operating Income Ratio | -3.63% | -4.43% | 3.33% | -3.71% | -14.23% | -7.57% | -16.75% | -93.40% | -44.36% | 0.00% | -82.41% | -235.07% |
| Total Other Income/Expenses | -131.19M | -65.72M | 12.61M | -67.69M | -18.23M | -6.67M | -3.56M | -114.00K | 386.26M | -25.25M | 41.19M | 19.00K |
| Income Before Tax | -202.41M | -62.08M | -29.80M | -337.80M | -327.12M | -54.15M | -76.40M | -237.53M | 343.29M | -25.25M | 20.03M | -19.60M |
| Income Before Tax Ratio | -10.31% | -4.59% | -3.28% | -33.04% | -38.65% | -8.64% | -17.57% | -93.45% | 354.35% | 0.00% | 78.03% | -234.84% |
| Income Tax Expense | -89.37M | -43.38M | 483.00K | -3.55M | -21.54M | 40.00K | -6.64M | -10.76M | 23.48M | 0.00 | 8.00K | 337.00K |
| Net Income | -113.04M | -18.70M | -30.28M | -334.25M | -305.58M | -52.66M | -60.67M | -159.74M | 332.49M | -25.25M | 20.02M | -19.26M |
| Net Income Ratio | -5.76% | -1.38% | -3.34% | -32.69% | -36.10% | -8.40% | -13.95% | -62.84% | 343.21% | 0.00% | 78.00% | -230.81% |
| EPS | -1.28 | -0.20 | -0.35 | -3.94 | -3.71 | -0.68 | -0.94 | -3.55 | 13.14 | -0.66 | 0.06 | -1.13K |
| EPS Diluted | -1.28 | -0.20 | -0.35 | -3.94 | -3.71 | -0.68 | -0.94 | -3.55 | 6.93 | -0.66 | 0.06 | -1.13K |
| Weighted Avg Shares Out | 111.25M | 93.70M | 86.07M | 84.93M | 82.36M | 77.34M | 64.35M | 45.00M | 25.13M | 38.23M | 38.23M | 17.00K |
| Weighted Avg Shares Out (Dil) | 111.25M | 93.70M | 86.07M | 84.93M | 82.36M | 77.34M | 64.35M | 45.03M | 46.14M | 38.23M | 38.23M | 17.00K |
Evolent Health Announces Dan McCarthy Appointed as President, Frank J. Williams to Retire from Evolent's Board of Directors in 2023
Evolent Health: Improving Financials, But There's More
What Makes Evolent Health (EVH) a Strong Momentum Stock: Buy Now?
Evolent Health to Participate in the CG Growth Conference
Why Evolent Health Was Such a Healthy Stock Today
Evolent Health (EVH) Q2 Earnings and Revenues Beat Estimates
Evolent Health, Inc. (EVH) CEO Seth Blackley on Q2 2022 Results - Earnings Call Transcript
Evolent Health Announces Second Quarter 2022 Results
Evolent Health Is In Buy Zone Ahead Of Earnings Announcement
Evolent Health Named to Parity.org's Best Companies for Women to Advance List 2022
Source: https://incomestatements.info
Category: Stock Reports